Sharpless’ priorities reflect continuity with Gottlieb

Acting FDA Commissioner Ned Sharpless laid out similar priorities to those of his predecessor in an all-hands email sent Tuesday to FDA employees, including a push to approve generics and biosimilars, develop modern guidance for emerging technologies, and

Read the full 382 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE